考虑早期动态风险分层以指导分化型甲状腺癌患者从肿瘤随访中出院
该回顾性队列纳入2008至2012年接受全甲状腺切除和放射性碘治疗、6个月后达到卓越缓解的分化型甲状腺癌患者492例,中位随访7.9年,7例(1.4%)复发且均在初治后10年内。结论认为低危和中危且10年后仍缓解者复发风险极低,可考虑由初级保健提供者随访,但出院建议需进一步前瞻性研究确认。
要点
- 全甲状腺切除和放射性碘治疗后6个月达卓越缓解者,中位随访7.9年复发率1.4%(7/492)。
- 7例复发中1例初始为高危、3例中危、3例低危(2015 ATA指南分层)。
- 所有复发均在初治后10年内,其中4例在5年内。
核心结论
- 低危和中危分化型甲状腺癌患者在全甲状腺切除和放射性碘治疗后6个月达卓越缓解且10年后仍缓解者复发风险极低。
- 作者认为从该时间点起随访可由初级保健提供者承担,但这些出院建议需进一步前瞻性研究确认。
研究设计与样本
- 回顾性队列研究,纳入2008至2012年接受全甲状腺切除和放射性碘治疗的分化型甲状腺癌患者。
- 纳入标准为治疗后6个月达缓解,缓解标准依据2015 ATA指南:影像学阴性且抑制性甲状腺球蛋白<0.2 ng/mL或重组人促甲状腺激素刺激后甲状腺球蛋白<1 ng/mL。
- 721例接受治疗的患者中,158例因6个月时持续疾病被排除,71例因随访数据缺失被排除,最终纳入492例。
- 平均随访时间7.0年,中位随访时间7.9年(四分位距IQR 2.1-11.3)。
主要发现
- 492例患者中7例(1.4%)复发,其中1例初始按2015 ATA指南分层为高危、3例为中危、3例为低危。
- 所有复发均发生在初治后10年内,其中4例发生在最初5年内。
- 7例复发患者中,6例在最初8年内检测到甲状腺球蛋白升高和/或可疑淋巴结,最后1例在初治手术后10年检测到。
关键数值与推荐
- 缓解标准依据2015 ATA指南:影像学阴性且抑制性甲状腺球蛋白<0.2 ng/mL或重组人促甲状腺激素刺激后甲状腺球蛋白<1 ng/mL。
- 复发的定义是细胞学和/或组织学证实的颈部淋巴结转移或接受第二次放射性碘治疗。
临床怎么用
- 作者认为低危和中危且10年后仍缓解的分化型甲状腺癌患者复发风险极低,从该时间点起随访可考虑由初级保健提供者承担。
- 作者指出这些出院建议需进一步前瞻性研究确认。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The current dogma is a life-long follow-up for patients treated for follicular-derived differentiated thyroid cancers (DTC). Our primary objective was to determine the time to recurrence in a series of DTC patients with an excellent response to therapy 6 months after total thyroidectomy and radioiodine therapy. The secondary objectives were to determine the time to suspicion of recurrence and to identify factors associated with recurrence. Methods: This retrospective cohort study included patients treated for DTC between 2008 and 2012 and in remission 6 months after total thyroidectomy and radioiodine treatment. The criteria for remission were negative imaging and suppressed thyroglobulin (Tg) <0.2 ng/mL or rh-TSH-(recombinant human TSH) stimulated Tg <1 ng/mL according to the 2015 ATA (American Thyroid Association) guidelines. Recurrence was defined by cytologically and/or histologically proven cervical lymph node metastasis or the administration of a second radioiodine treatment. Results: Among 721 patients treated for DTC, 158 were excluded because of persistent disease at 6 months, 71 because of missing follow-up data, and 492 were included. The mean and median follow-up time were 7.0 and 7.9 years (interquartile range IQR [2.1-11.3]). Recurrence occurred for 7 patients (1.4%), 1 initially classified as high recurrence risk, 3 as intermediate, and 3 as low risk according to the 2015 ATA guidelines. All relapses occurred within 10 years after initial management (4 within the first 5 years). For patients with recurrence, rise in Tg and/or suspicious lymph nodes were detected in six out of seven cases in the first 8 years and for the last case 10 years after initial surgery. Conclusion: Low and intermediate recurrence risk DTC patients with excellent response 6 months after total thyroidectomy and radioiodine and in remission 10 years later have an extremely low recurrence risk. Follow-up might be undertaken by primary care providers from this time point. These discharge recommendations should be confirmed by further prospective studies.
引用
- Attia A, Touma E, Lussey-Lepoutre C, et al. Consideration of Early Dynamic Risk Stratification to Guide Discharge from Oncologic Follow-Up in Patients with Differentiated Thyroid Cancer. Thyroid. 2024. PMID: 39287064. doi:10.1089/thy.2024.0119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。